Skip to main
NRSN
NRSN logo

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics is positioned for growth due to favorable Phase 2b PARADIGM study results, which indicated a statistically significant 29.2% slowing of disease progression in patients, with even higher efficacy among early treatment groups. The company's commitment to investigating novel therapies derived from FDA-approved medications, coupled with strong safety and tolerability data, enhances its attractiveness for potential strategic partnerships in North America and Europe. Furthermore, ongoing regulatory progress, including anticipated Canadian approval, could facilitate lucrative commercial partnerships that may provide non-dilutive capital, thereby enhancing the company’s financial stability and viability in the neurodegenerative disease treatment market.

Bears say

NeuroSense Therapeutics is facing a negative outlook primarily due to tightening cash reserves, which raises concerns regarding its financial stability and operational longevity. The company is anticipated to require a capital raise to sustain ongoing projects and development efforts, indicating potential liquidity issues. Such financial pressures could hinder progress on its key product candidate, PrimeC, thereby negatively affecting investor confidence and market performance.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.